Is lurbinectedin approved by the fda for all cancers?

Is lurbinectedin approved for cancers other than small cell lung cancer?

Lurbinectedin received FDA approval in June 2020 under the accelerated approval pathway for adults with metastatic small cell lung cancer whose disease progressed after platinum-based chemotherapy. The agency granted this approval solely based on a single-arm phase 2 study showing overall response rates in patients with prior treatment.

Does the FDA limit use of lurbinectedin to a single indication?

The FDA currently restricts lurbinectedin to the metastatic small cell lung cancer setting. No other cancer types have received approval for this drug. Data from ongoing trials in other tumor types remain under review.

What happens if lurbinectedin is used outside its approved indication?

Physicians may prescribe lurbinectedin off-label for other cancers, but insurance coverage and reimbursement often depend on published clinical evidence and the availability of better-supported alternatives. Off-label use carries regulatory and clinical risks if comprehensive data do not exist.

When might lurbinectedin receive approval for broader cancer types?

Lurbinectedin is now tested in several ongoing clinical trials for ovarian cancer, sarcoma, and soft tissue tumors. Approval for new indications will require positive phase 3 results submitted to the FDA along with evidence demonstrating clinical benefit.